TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26843154
Drug: Soy isoflavones
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavones (80 mg aglycone equivalents)
Study: 26843154
Drug: Commercially produced
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially produced S-(−)equol (40 mg)
Study: 22585228
Drug: Rifaximin 25
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin 25 mg/day for 5 days
Study: 22585228
Drug: Rifaximin 100
Normalized name: rifaximin 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 100 mg/day for 5 days
Study: 22585228
Drug: Rifaximin 100
Normalized name: rifaximin 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 100 mg/day for 2 days
Study: 9922309
Drug: Oral budesonide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral budesonide, 6 mg daily
Study: 28106611
Drug: High-dose fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose fentanyl
Study: 26027628
Drug: Half-dose tenecteplase
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Half-dose tenecteplase (TNK) post-amendment (50% reduction in dose)
Study: 26027628
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose tenecteplase (TNK) pre-amendment
Study: 26027628
Drug: Half-dose tenecteplase
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Half-dose tenecteplase (TNK) post-amendment
Study: 12971512
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) - Group 1: intravenous loading dose of 140 mg/kg followed by 70 mg/kg every four hours for up to 18 doses
Study: 12971512
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) - Group 2: a single intravenous loading dose followed by oral NAC in the same amount as for Group 1
Study: 12971512
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) - Group 3: regimen identical to Group 1 except that oral NAC was administered after the first 24 hours
Study: 8630635
Drug: Diclofenac 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 100 mg slow release once daily
Study: 29274118
Drug: Escalating doses
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses of methotrexate (C-MTX)
Study: 28566632
Drug: Low-caffeine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-caffeine green tea (≥500 mL/d, with theanine ca. 15 mg/d)
Study: 25783756
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT), 30 sessions
Study: 20505665
Drug: Posaconazole oral
Normalized name: posaconazole Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole oral suspension (POS) 200 mg three times daily (t.i.d.)
Study: 18378519
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (indapamide 1.5 mg sustained release)
Study: 12745193
Drug: DASH diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: DASH diet with losartan 50 mg daily
Study: 12745193
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet with losartan 50 mg daily
Study: 8793606
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg tablet for 7 days
Study: 1627417
Drug: Sequential methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sequential methotrexate and fluorouracil (MTX-5-FU) followed by leucovorin
Study: 2680430
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 to 360 mg/day)
Study: 6744774
Drug: Methyldopa (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa (500 to 2500 mg/day)
Study: 22748820
Drug: Intravenous aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous aspirin (300 mg) within 90 min after alteplase treatment
Study: 22748820
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (alteplase without aspirin)
Study: 17609331
Drug: Home-based physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based physical therapy intervention
Study: 8861829
Drug: PMEA (9-(2-phosphonylmethoxyethyl)adenine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMEA (9-(2-phosphonylmethoxyethyl)adenine) administered intravenously at a dose of 1000 mg weekly for 11 weeks
Study: 1731046
Drug: Naloxone (0.05,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.05, 0.10, 0.15 and 0.20 mg)
Study: 29897851
Drug: 0.9% sodium
Normalized name: LMD with 0.9% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride content, rapid rate of administration
Study: 29897851
Drug: 0.9% sodium
Normalized name: LMD with 0.9% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride content, slow rate of administration
Study: 29897851
Drug: 0.45% sodium
Normalized name: Dextrose 5% and 0.45% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45% sodium chloride content, rapid rate of administration
Study: 29897851
Drug: 0.45% sodium
Normalized name: Dextrose 5% and 0.45% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45% sodium chloride content, slow rate of administration
Study: 27132415
Drug: Piroxicam 10
Normalized name: piroxicam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 10 mg/day on days 4-6 after IUI
Study: 20712131
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of oral activated charcoal (50 g) given 30 min after drugs
Study: 20712131
Drug: Repeated doses
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated doses of oral activated charcoal (20 g) given 6-72 h after LTG
Study: 20712131
Drug: Repeated doses
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated doses of oral activated charcoal (20 g) given 12-48 h after OXC
Study: 10085281
Drug: Topical crude
Normalized name: COAL TAR,CRUDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical crude honey (12 hourly application)
Study: 2264899
Drug: Local anesthesia
Normalized name: Esters of benzoic acid for local anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthesia with intravenous sedation (fentanyl, midazolam, or combinations thereof)
Study: 2264899
Drug: Fentanyl, midazolam,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl, midazolam, and fentanyl/midazolam combinations as intravenous supplements
Study: 6449360
Drug: Carbenicillin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbenicillin (6 g/m(2) . 6 h) plus sisomicin (45 g/m2 . 6 h)
Study: 6449360
Drug: Mezlocillin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mezlocillin (3 g/m2 . 6 h) plus sisomicin (45 g/m2 . 6 h)
Study: 16459230
Drug: 0.4 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 g/d of PSE in DAG-containing mayonnaise
Study: 16459230
Drug: 0.3 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g/d of PSE in DAG-containing mayonnaise
Study: 11298175
Drug: Midazolam 0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.04 mg kg(‐1) (group 2)
Study: 11298175
Drug: Midazolam 0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.04 mg kg(‐1) and lidocaine 1.5 mg kg(‐1) (group 3)
Study: 11298175
Drug: Fentanyl 1
Normalized name: fentanyl 1.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1 microg kg(‐1) and lidocaine 1.5 mg kg(‐1) (group 1)
Study: 11298175
Drug: Midazolam 0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.04 mg kg(‐1) (groups 2 and 3)
Study: 9392406
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol (200 microg thrice daily for 14 days)
Study: 9392406
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol (600 microg single inhalation after 14 days treatment)
Study: 9392406
Drug: Placebo (thrice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (thrice daily for 14 days)
Study: 8017589
Drug: Propofol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2.5 mg.kg‐1 b.w.)
Study: 8017589
Drug: Thiopentone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone (5 mg.kg‐1 b.w.)
Study: 8017589
Drug: Etomidate (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate (0.2 mg.kg‐1 b.w.)
Study: 8017589
Drug: Flunitrazepam and
Normalized name: flunitrazepam
DrugBank: Flunitrazepam (DB01544)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam and fentanyl (0.005 mg.kg‐1 b.w.)
Study: 2465099
Drug: Active antiarrhythmic
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active antiarrhythmic therapy (various drugs including encainide and flecainide)
Study: 2465099
Drug: Encainide and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encainide and flecainide treatments
Study: 2465099
Drug: Active therapies
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active therapies (general)
Study: 62111
Drug: Warfarin sodium
Normalized name: Warfarin Sodium
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin sodium (doses aimed at maintaining a 'Thrombotest' value of 10%, given from the day of admission until independent mobility or for 3 months)
Study: 31444192
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual with a wearable device
Study: 26279111
Drug: L-T4 treatment
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-T4 treatment (1.6 µg/kg daily)
Study: 23430723
Drug: Specific antibiotics
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific antibiotics (Group A)
Study: 23430723
Drug: No specific
Normalized name: Oregano specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: No specific antibiotics (Group B)
Study: 18257346
Drug: Pricking blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pricking blood therapy combined with acupuncture
Study: 18257346
Drug: Routine western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine western medicine (Aciclovir plaster and Aciclovir tablets)
Study: 17846273
Drug: Isotonic sodium
Normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic sodium chloride solution (placebo)
Study: 11495138
Drug: Active dental
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active dental gel (lidocaine 25 mg/g plus prilocaine 25 mg/g)
Study: 9728853
Drug: Oral antihistamines
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antihistamines (diphenhydramine ≤ 1 mg/kg and cimetidine ≤ 4 mg/kg)
Study: 29663959
Drug: 4-drug fixed-dose
Normalized name: 4-MIXED TRACE ELEMENTS INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-drug fixed-dose combination (4FDC)
Study: 29663959
Drug: 2-drug fixed-dose
Normalized name: ALLERGENIC EXTRACT, 2 GRASS MIX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-drug fixed-dose combination (2FDC)
Study: 29663959
Drug: Single-drug reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-drug reference
Study: 14499320
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) as monotherapy (n=7) or adjunctive therapy to carbamazepine (CBZ) (n=2) at dosages ranging from 25 mg to 100 mg twice daily
Study: 10707873
Drug: rHuIL-12 (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuIL-12 (higher doses)
Study: 28459732
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (fluid therapy based on traditional principles)
Study: 26242578
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg twice daily, increased to 1000 mg twice daily over 6 weeks)
Study: 21690510
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate nasal spray, 55 μg/nostril daily for 2 weeks
Study: 17205943
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy plus epidural injection of 80 mg methylprednisolone and 10 mg bupivacaine
Study: 17205943
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (oral antiviral agents and analgesics) alone
Study: 10960626
Drug: Raloxifene 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 150 mg/day
Study: 14610642
Drug: HRT (Premarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT (Premarin 0.625 mg/day, and Provera 2.5 mg/day)
Study: 2890150
Drug: Famotidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (20 mg at night)
Study: 2890150
Drug: Ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (300 mg at night)
Study: 2890150
Drug: All drugs
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All drugs (Famotidine and Ranitidine)
Study: 29707200
Drug: Simvastatin administration
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin administration
Study: 27841968
Drug: Low-Level Laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Level Laser Therapy (LLLT) applied at 10 points through the surgical scar in three sessions.
Study: 22534479
Drug: PE+MARS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PE+MARS treatment
Study: 20862935
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (Captopril)
Study: 18187817
Drug: Hydroxychloroquine 200
Normalized name: hydroxychloroquine 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine 200 mg twice daily for the first month and 200 mg once daily for the next month (total duration 2 months)
Study: 18187817
Drug: Chloroquine 250
Normalized name: chloroquine 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine 250 mg twice daily for the first month and 250 mg once daily for the next month (total duration 2 months)
Study: 12940470
Drug: Preparing for
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparing for the Drug Free Years Program (PDFY)
Study: 10485271
Drug: Interferon-alpha (IFN-alpha)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha (IFN-alpha) administered 2 h before cyclophosphamide (CP)
Study: 10485271
Drug: Interferon-alpha (IFN-alpha)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha (IFN-alpha) administered 24 h after cyclophosphamide (CP)
Study: 7815355
Drug: Naproxen (oral)
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen (oral)
Study: 7815355
Drug: Tenidap (oral)
Normalized name: tenidap
DrugBank: Tenidap (DB13481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenidap (oral)
Study: 1657084
Drug: Perindopril (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (2 mg)
Study: 7104466
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg dose of chlorothiazide
Study: 7104466
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg dose of chlorothiazide
Study: 7104466
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg dose of chlorothiazide
Study: 29030775
Drug: Prednisolone treatment
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone treatment for three cycles of 21 days
Study: 22518827
Drug: 10 mM
Normalized name: potassium 10 MMOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mM l‐NAME
Study: 22518827
Drug: Combined 10
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined 10 mM l‐NAME + 20 mM capsazepine
Study: 12507112
Drug: High-dose irradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose irradiation (mean margin dose of 52.1 Gy)
Study: 12507112
Drug: Low-dose irradiation
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose irradiation (mean margin dose of 41.5 Gy)
Study: 9578044
Drug: Extended-release carbamazepine
Normalized name: carbamazepine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release carbamazepine (CBZ) twice daily
Study: 9578044
Drug: Immediate-release carbamazepine
Normalized name: carbamazepine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release carbamazepine (CBZ) four times daily
Study: 33086
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium (550 mg at first sign of pain, then 275 mg every six hours as needed)
Study: 23031209
Drug: Group-housed (G)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-housed (G)
Study: 11554706
Drug: Moisturising cream
Normalized name: capsaicin Topical Cream [Arthricare for Women Moisturizing]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moisturising cream applied for 14 days
Study: 9255718
Drug: Chitosan (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitosan (30 tablets, 45 mg/tablet, three times a day)
Study: 9255718
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (1 week prior to chitosan ingestion)
Study: 8332651
Drug: Clonidine 0.3
Normalized name: CLONIDINE 0.3MG/24HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 0.3 mg b.d. for two weeks
Study: 3089439
Drug: Prednisolone (steroids)
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone (steroids) for 3 days
Study: 24595149
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml (15 mg) 0.5% isobaric levobupivacaine (group L)
Study: 24595149
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml (15 mg) of 0.5% hyperbaric bupivacaine (group B)
Study: 21929835
Drug: EPA (1·67
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA (1·67 g EPA + 0·16 g DHA/d)
Study: 21929835
Drug: DHA (1·55
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA (1·55 g DHA + 0·40 g EPA/d)
Study: 21929835
Drug: LA (2·2
Approvals — FDA: no, EMA: no, PMDA: no
Description: LA (2·2 g/d)
Study: 20197484
Drug: Necitumumab 800
Normalized name: necitumumab 800 MG in 50 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Necitumumab 800 mg (flat dosing)
Study: 20197484
Drug: Necitumumab 600
Normalized name: Necitumumab
DrugBank: Necitumumab (DB09559)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Necitumumab 600 mg or more
Study: 20197484
Drug: Necitumumab 1000
Normalized name: Necitumumab
DrugBank: Necitumumab (DB09559)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Necitumumab 1000 mg every 2 weeks
Study: 18806204
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied NTG ointment (2%)
Study: 18806204
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied NTG ointment (2%) + treadmill ambulation
Study: 16894463
Drug: Ticlopidine 250
Normalized name: ticlopidine 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine 250 mg daily (before July 1999) or Clopidogrel 75 mg daily (after July 1999) for one month
Study: 8851903
Drug: Diuretic plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic plus exercise training (D+E)
Study: 6647208
Drug: metoprolol (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol (all formulations)
Study: 31203725
Drug: Nilvadipine treatment
Normalized name: nilvadipine
DrugBank: Nilvadipine (DB06712)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilvadipine treatment
Study: 20646099
Drug: Cholecalciferol 1,000
Normalized name: CHOLECALCIFEROL 1,000UNIT CAP,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 1,000 IU/day (daily D(3) group)
Study: 15754269
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of modified‐release aspirin daily
Study: 15754269
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of simvastatin daily
Study: 7023526
Drug: SHRZ6 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHRZ6 and EHRZ6 regimens (6 months, daily isoniazid and rifampicin, supplemented by streptomycin and pyrazinamide for the first two months)
Study: 7023526
Drug: EHR9 regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: EHR9 regimen (9 months, daily isoniazid and rifampicin, supplemented by ethambutol for the first two months)
Study: 7023526
Drug: SHRZ6 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHRZ6 and EHRZ6 regimens (6 months, daily isoniazid and rifampicin, supplemented by pyrazinamide)
Study: 7023526
Drug: EHR9 regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: EHR9 regimen (9 months, daily isoniazid and rifampicin, supplemented by ethambutol)
Study: 30918097
Drug: Trofinetide 200
Normalized name: trofinetide 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trofinetide 200 mg/kg bid